Voltaren topical pain relief gel for everyday joints

Voltaren pain relief gel brings targeted, over-the-counter relief for aching joints and muscles in adults. Here is how it works, where it fits in daily life, and what US users should know before choosing it.

Voltaren pain relief gel is a topical nonsteroidal anti-inflammatory drug (NSAID) used to relieve joint pain in adults and is sold over the counter in the United States as Voltaren Arthritis Pain Gel for osteoarthritis of joints such as knees, hands, and feet (Voltaren US, 03/01/2024; FDA, 07/29/2020).

Updated: 05/17/2026 | Reading time: approx. 9 minutes

By the AD HOC NEWS editorial team - specialized in product-led market coverage.

At a Glance

• Product: Voltaren pain relief gel
• Category: Topical NSAID pain relief gel
• Brand/Manufacturer: Voltaren / Haleon
• Main Use Cases: Relief of osteoarthritis joint pain in adults
• Availability: Over the counter in US pharmacies and retailers
• Key Markets: North America, Europe, selected global markets

What Voltaren pain relief gel Is and How It Works

Voltaren pain relief gel in the US contains the active ingredient diclofenac sodium 1 percent, a nonsteroidal anti-inflammatory drug that helps relieve joint pain from osteoarthritis in adults when applied to affected joints such as hands, wrists, elbows, knees, ankles, and feet (FDA, 07/29/2020; Voltaren US, 03/01/2024).

As a topical NSAID, Voltaren is applied directly to the skin over the painful joint, where diclofenac is absorbed locally to reduce pain and inflammation in the underlying tissues, rather than being taken orally as a pill (FDA, 07/29/2020; Mayo Clinic, 11/01/2023).

The gel formulation is designed to be massaged into the skin and used on specific joints up to a labeled maximum number of times per day and for a defined treatment duration, which consumers are instructed to follow as directed on the Drug Facts label or by a health care professional (Voltaren US, 03/01/2024; FDA, 07/29/2020).

Topical NSAID basics

Topical NSAIDs like Voltaren deliver an anti-inflammatory ingredient through the skin to the local tissues under the application site, which can help limit systemic exposure compared with some oral NSAIDs, while still offering pain relief for certain conditions when used as directed (Mayo Clinic, 08/01/2023; Arthritis Foundation, 04/10/2023).

The Arthritis Foundation notes that topical NSAIDs may be particularly useful for joints that are close to the skin surface, such as hands and knees, and that they are one of several non-opioid options for managing osteoarthritis discomfort when used according to labeling and medical advice (Arthritis Foundation, 04/10/2023; CDC, 02/01/2024).

Labeling, indications, and limits

In the United States, Voltaren Arthritis Pain Gel is labeled for the temporary relief of joint pain from osteoarthritis in adults 18 years and older and is not indicated for back, muscle, or sports injuries, which is specified in the Drug Facts label and FDA communications on the over-the-counter switch (FDA, 07/29/2020; Voltaren US, 03/01/2024).

The product labeling also outlines important warnings, including not using the gel on more than two body areas at the same time and avoiding use in children, pregnant women in late pregnancy, and individuals with certain NSAID-related allergy or health histories, which consumers should review before use (Voltaren US, 03/01/2024; FDA, 07/29/2020).

Why Voltaren pain relief gel Matters for Consumers and Industry

For US consumers, Voltaren pain relief gel represents an over-the-counter treatment option for osteoarthritis joint pain that was previously available only by prescription in the United States, giving adults a nonprescription choice that can be used without a new doctor visit when appropriate (FDA, 07/29/2020; Consumer Reports, 09/15/2023).

Osteoarthritis affects millions of adults in the United States, and the Centers for Disease Control and Prevention highlight that non-opioid pain relief strategies such as topical and oral medications, physical activity, and weight management play an important role in managing symptoms and preserving mobility (CDC, 02/01/2024; CDC, 10/30/2023).

Because Voltaren is available without a prescription, it is stocked in many US pharmacies, supermarkets, and online retailers, which supports convenient access within the framework of FDA-approved labeling and over-the-counter drug monograph standards that apply to topical NSAID products (Voltaren US, 03/01/2024; FDA, 12/14/2023).

Role in daily routines and self-care

Voltaren pain relief gel is often positioned by the brand and US health publications as part of an overall joint health routine that can also include low-impact exercise, physical therapy, joint-friendly activities, and other non-drug approaches recommended by clinicians for people living with osteoarthritis (Voltaren US, 03/01/2024; Arthritis Foundation, 06/20/2023).

The Arthritis Foundation notes that people with osteoarthritis often benefit from individualized care plans that may include topical medications like diclofenac gel along with joint protection techniques, assistive devices, and lifestyle adjustments to help manage pain and maintain participation in work and daily tasks (Arthritis Foundation, 04/10/2023; Arthritis Foundation, 01/12/2024).

Industry and healthcare context

From an industry perspective, the move of diclofenac gel to over-the-counter status for Voltaren in the US is described by FDA communications and business press as part of a broader shift toward consumer self-care products that give patients more direct control over managing common conditions under clear risk management frameworks (FDA, 07/29/2020; Wall Street Journal, 07/26/2021).

Business coverage of the Haleon consumer health portfolio, which includes Voltaren, emphasizes how over-the-counter pain relief brands sit at the intersection of pharmaceuticals and everyday consumer goods, requiring strong regulatory compliance and extensive education to help users understand appropriate use and potential risks (Financial Times, 07/18/2022; Haleon, 10/15/2024).

Voltaren pain relief gel in the US and Global Market

Voltaren pain relief gel is part of a global Voltaren brand family marketed by consumer health company Haleon in many countries, with specific formulations, indications, and regulatory classifications that can differ between regions, including prescription and over-the-counter versions (Haleon, 10/15/2024; Voltaren US, 03/01/2024).

In the United States, Voltaren Arthritis Pain Gel is available as an over-the-counter medication for adults and sits on store shelves alongside other topical pain options such as menthol-based rubs and lidocaine patches, with US consumer guides often comparing label indications, age limits, and safety profiles among these categories rather than endorsing one product over another (Consumer Reports, 09/15/2023; Harvard Health, 02/05/2024).

Globally, Voltaren-branded products include various diclofenac formulations such as gels, tablets, and other topical forms, and they are part of the arthritis and pain relief segment that analysts at industry research firms describe as supported by aging populations and growing attention to self-managed musculoskeletal conditions, within tight regulatory oversight for NSAID safety (Haleon, 10/15/2024; Statista, 01/10/2024).

• Topical NSAID gel for osteoarthritis joint pain relief in adults when used as directed.
• Over-the-counter status in the US, available in pharmacies, supermarkets, and online.
• Part of a global Voltaren portfolio within the Haleon consumer health business.

Behind Voltaren pain relief gel is the Voltaren brand within the Haleon consumer health portfolio, which was previously part of a joint venture structure involving GSK and Novartis in certain markets before being consolidated under Haleon as a dedicated consumer health company (Haleon, 10/15/2024; Novartis, 03/27/2018).

Novartis, historically linked to Voltaren through earlier joint venture structures and prescription diclofenac products, is listed on the SIX Swiss Exchange under the ticker NOVN and on the New York Stock Exchange via American Depositary Receipts, with the ISIN CH0012005267 used for the Swiss listing (Novartis, 12/12/2024; SIX Swiss Exchange, 01/05/2025).

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.